Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Description

This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.

Conditions

Plasma Cell Myeloma

Talk to us

Study Overview

On this page

Study Details

Study overview

This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.

The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Condition
Plasma Cell Myeloma
Intervention / Treatment

-

Contacts and Locations

New Brunswick

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States, 08903

New Brunswick

RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Brunswick, New Jersey, United States, 08903

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient must be able to provide informed consent
  • * Patients with confirmed diagnosis of multiple myeloma
  • * Able to swallow and retain oral medication
  • * All ethnic groups are eligible
  • * Non-English speaking person
  • * Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant
  • * Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
  • * Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study
  • * On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Rutgers, The State University of New Jersey,

Mansi R. Shah, MD, PRINCIPAL_INVESTIGATOR, Rutgers Cancer Institute of New Jersey

Study Record Dates

2025-06-30